Published in Mol Biol Cell on March 26, 2004
Endothelin-1 induces alveolar epithelial-mesenchymal transition through endothelin type A receptor-mediated production of TGF-beta1. Am J Respir Cell Mol Biol (2007) 2.50
Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol (2006) 1.87
CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol Biol Cell (2004) 1.83
Semaphorin 7A plays a critical role in TGF-beta1-induced pulmonary fibrosis. J Exp Med (2007) 1.67
Whole animal knockout of smooth muscle alpha-actin does not alter excisional wound healing or the fibroblast-to-myofibroblast transition. Wound Repair Regen (2012) 1.47
Retracted GSK-3beta in mouse fibroblasts controls wound healing and fibrosis through an endothelin-1-dependent mechanism. J Clin Invest (2008) 1.46
How does endothelial cell injury start? The role of endothelin in systemic sclerosis. Arthritis Res Ther (2007) 1.40
Dynamic actin remodeling during epithelial-mesenchymal transition depends on increased moesin expression. Mol Biol Cell (2011) 1.38
The adventitia: essential regulator of vascular wall structure and function. Annu Rev Physiol (2012) 1.31
Endothelin receptors and pain. J Pain (2009) 1.27
Myofibroblasts: trust your heart and let fate decide. J Mol Cell Cardiol (2013) 1.25
Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol (2011) 1.24
Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anti-cancer therapy? Semin Cell Dev Biol (2009) 1.23
Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J Gastroenterol (2008) 1.23
Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol (2009) 1.20
FAK is required for TGFbeta-induced JNK phosphorylation in fibroblasts: implications for acquisition of a matrix-remodeling phenotype. Mol Biol Cell (2007) 1.19
Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum (2009) 1.14
The role of connective tissue growth factor (CTGF/CCN2) in skeletogenesis. Crit Rev Eukaryot Gene Expr (2011) 1.11
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur Heart J (2008) 1.10
Periostin modulates myofibroblast differentiation during full-thickness cutaneous wound repair. J Cell Sci (2012) 1.09
Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis (2006) 1.08
Periostin differentially induces proliferation, contraction and apoptosis of primary Dupuytren's disease and adjacent palmar fascia cells. Exp Cell Res (2009) 1.07
Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation. Arthritis Rheum (2012) 1.06
Scar wars: is TGFbeta the phantom menace in scleroderma? Arthritis Res Ther (2006) 1.05
Rac1 expression by fibroblasts is required for tissue repair in vivo. Am J Pathol (2009) 1.03
Transcriptional regulation of monocyte chemotactic protein-1 release by endothelin-1 in human airway smooth muscle cells involves NF-kappaB and AP-1. Br J Pharmacol (2009) 1.01
The role of the paracrine/autocrine mediator endothelin-1 in regulation of cardiac contractility and growth. Br J Pharmacol (2013) 1.00
Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis. Int J Biochem Cell Biol (2011) 0.99
Epithelial-mesenchymal interactions in pulmonary fibrosis. Semin Respir Crit Care Med (2006) 0.99
Inhibiting toll-like receptor 4 signaling ameliorates pulmonary fibrosis during acute lung injury induced by lipopolysaccharide: an experimental study. Respir Res (2009) 0.99
Antibodies against human cytomegalovirus in the pathogenesis of systemic sclerosis: a gene array approach. PLoS Med (2005) 0.98
Endothelin-1 increases collagen accumulation in renal mesangial cells by stimulating a chemokine and cytokine autocrine signaling loop. J Biol Chem (2010) 0.97
Proteomic analysis of CTGF-activated lung fibroblasts: identification of IQGAP1 as a key player in lung fibroblast migration. Am J Physiol Lung Cell Mol Physiol (2008) 0.95
In vitro wounding: effects of hypoxia and transforming growth factor beta1 on proliferation, migration and myofibroblastic differentiation in an endothelial cell-fibroblast co-culture model. J Mol Histol (2007) 0.94
Rac inhibition reverses the phenotype of fibrotic fibroblasts. PLoS One (2009) 0.94
Cell permeant peptide analogues of the small heat shock protein, HSP20, reduce TGF-beta1-induced CTGF expression in keloid fibroblasts. J Invest Dermatol (2008) 0.94
Endothelin-1 promotes osteosarcoma cell invasion and survival against cisplatin-induced apoptosis. Clin Orthop Relat Res (2011) 0.94
Interstitial lung disease in systemic sclerosis. Lung (2007) 0.94
Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis. Arthritis Res Ther (2014) 0.94
Effects of interleukin-18 on cardiac fibroblast function and gene expression. Cytokine (2010) 0.93
Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease. Curr Drug Targets (2011) 0.93
X-linked inhibitor of apoptosis regulates lung fibroblast resistance to Fas-mediated apoptosis. Am J Respir Cell Mol Biol (2013) 0.92
Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription. Am J Physiol Cell Physiol (2014) 0.92
Lipoxin A4 modifies platelet-derived growth factor-induced pro-fibrotic gene expression in human renal mesangial cells. Am J Pathol (2005) 0.92
dsRNA activation of endothelin-1 and markers of vascular activation in endothelial cells and fibroblasts. Ann Rheum Dis (2010) 0.92
Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist. Transl Oncol (2012) 0.92
Endothelin-1 stimulates contraction and migration of rat pancreatic stellate cells. World J Gastroenterol (2005) 0.91
Therapeutic targets in systemic sclerosis. Arthritis Res Ther (2007) 0.91
Towards an anti-fibrotic therapy for scleroderma: targeting myofibroblast differentiation and recruitment. Fibrogenesis Tissue Repair (2010) 0.90
Reversal of myofibroblast differentiation by prostaglandin E(2). Am J Respir Cell Mol Biol (2013) 0.90
Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy. Treat Respir Med (2006) 0.90
Possible strategies for anti-fibrotic drug intervention in scleroderma. J Cell Commun Signal (2011) 0.89
The interplay of the Notch signaling in hepatic stellate cells and macrophages determines the fate of liver fibrogenesis. Sci Rep (2015) 0.88
Innovative approaches to the therapy of fibrosis. Curr Opin Rheumatol (2009) 0.88
Systemic vasculopathy with altered vasoreactivity in a transgenic mouse model of scleroderma. Arthritis Res Ther (2010) 0.88
Akt1 mediates α-smooth muscle actin expression and myofibroblast differentiation via myocardin and serum response factor. J Biol Chem (2013) 0.88
Periostin induces intracellular cross-talk between kinases and hyaluronan in atrioventricular valvulogenesis. J Biol Chem (2014) 0.88
Diabetes-induced alterations in the extracellular matrix and their impact on myocardial function. Microsc Microanal (2012) 0.88
The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis. BioDrugs (2010) 0.86
Differentiation potential of CD14+ monocytes into myofibroblasts in patients with systemic sclerosis. PLoS One (2012) 0.86
Fibronectin stimulates endothelin-1 synthesis in rat hepatic myofibroblasts via a Src/ERK-regulated signaling pathway. Gastroenterology (2009) 0.85
Functional and phenotypical comparison of myofibroblasts derived from biopsies and bronchoalveolar lavage in mild asthma and scleroderma. Respir Res (2006) 0.85
The adventitia: Essential role in pulmonary vascular remodeling. Compr Physiol (2011) 0.85
Cardioprotective signaling by endothelin. Trends Cardiovasc Med (2008) 0.84
Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1. Arthritis Res Ther (2014) 0.83
Systemic Sclerosis-Associated Interstitial Lung Disease: Lessons from Clinical Trials, Outcome Measures, and Future Study Design. Curr Rheumatol Rev (2010) 0.82
Inhibition of angiogenesis by platelets in systemic sclerosis patients. Arthritis Res Ther (2015) 0.82
Blockade of endothelinergic receptors prevents development of proliferative vitreoretinopathy in mice. Am J Pathol (2008) 0.82
Endothelial cells direct human mesenchymal stem cells for osteo- and chondro-lineage differentiation through endothelin-1 and AKT signaling. Stem Cell Res Ther (2015) 0.82
Urotensin-II in systemic sclerosis: a new peptide in pathogenesis. Clin Rheumatol (2011) 0.81
Integrin β1 is required for maintenance of vascular tone in postnatal mice. J Cell Commun Signal (2012) 0.81
Vascular changes in bleomycin-induced scleroderma. Int J Rheumatol (2011) 0.81
Angiotensin-II induces phosphorylation of ERK1/2 and promotes aortic adventitial fibroblasts differentiating into myofibroblasts during aortic dissection formation. J Mol Histol (2013) 0.80
Endothelin Receptors Expressed by Immune Cells Are Involved in Modulation of Inflammation and in Fibrosis: Relevance to the Pathogenesis of Systemic Sclerosis. J Immunol Res (2015) 0.80
Ambrisentan for the treatment of pulmonary arterial hypertension. Drug Des Devel Ther (2009) 0.79
Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts. Arthritis Res Ther (2015) 0.79
Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension. Respir Res (2009) 0.78
Effectiveness of palosuran in bleomycin-induced experimental scleroderma. Inflammation (2013) 0.77
Getting out of a sticky situation: targeting the myofibroblast in scleroderma. Open Rheumatol J (2012) 0.77
Protein Expression by Human Pulmonary Artery Smooth Muscle Cells Containing a BMPR2 Mutation and the Action of ET-1 as Determined by Proteomic Mass Spectrometry. Int J Mass Spectrom (2015) 0.77
Cell-type-specific differentiation and molecular profiles in skin transplantation: implication of medical approach for genetic skin diseases. J Transplant (2011) 0.77
Effect of CTRP3 on activation of adventitial fibroblasts induced by TGF-β1 from rat aorta in vitro. Int J Clin Exp Pathol (2014) 0.77
Hydroxyurea therapy for priapism prevention and erectile function recovery in sickle cell disease: a case report and review of the literature. Int Urol Nephrol (2014) 0.77
Stimulation of Transforming Growth Factor-β1-Induced Endothelial-To-Mesenchymal Transition and Tissue Fibrosis by Endothelin-1 (ET-1): A Novel Profibrotic Effect of ET-1. PLoS One (2016) 0.76
Molecular pathophysiology of priapism: emerging targets. Curr Drug Targets (2015) 0.76
Thrombin-induced CCN2 expression as a target for anti-fibrotic therapy in scleroderma. J Cell Commun Signal (2009) 0.76
Analysis of immunostaining and western blotting of endothelin 1 and its receptors in mitral stenosis. Rev Bras Cir Cardiovasc (2015) 0.76
Arsenic Promotes NF-Κb-Mediated Fibroblast Dysfunction and Matrix Remodeling to Impair Muscle Stem Cell Function. Stem Cells (2016) 0.75
Animal models of systemic sclerosis: their utility and limitations. Open Access Rheumatol (2014) 0.75
Medical therapies for pulmonary arterial hypertension. Heart Fail Rev (2016) 0.75
Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol (2002) 14.80
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem (1994) 14.36
Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem (1998) 13.93
A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A (1995) 10.25
SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett (1995) 9.62
The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal (2002) 6.35
Protein kinase B (c-Akt): a multifunctional mediator of phosphatidylinositol 3-kinase activation. Biochem J (1998) 6.28
Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. Proc Natl Acad Sci U S A (1979) 6.09
Signal transduction by the TGF-beta superfamily. Science (2002) 5.61
Fibroblasts, myofibroblasts, and wound contraction. J Cell Biol (1994) 4.60
Fibroblast biology in three-dimensional collagen matrices. Trends Cell Biol (2003) 4.55
Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol (2001) 4.43
PI3K/Akt and apoptosis: size matters. Oncogene (2003) 4.35
The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol (1998) 3.65
CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem (2001) 3.28
Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice. Proc Natl Acad Sci U S A (2002) 3.18
Paxillin: a focal adhesion-associated adaptor protein. Oncogene (2001) 3.03
Endothelins. N Engl J Med (1995) 2.52
Mechanisms of force generation and transmission by myofibroblasts. Curr Opin Biotechnol (2003) 2.43
Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem (2003) 2.35
The extracellular matrix as a scaffold for tissue reconstruction. Semin Cell Dev Biol (2002) 2.31
Blockage of chemotactic peptide-induced stimulation of neutrophils by wortmannin as a result of selective inhibition of phosphatidylinositol 3-kinase. J Biol Chem (1994) 2.31
Mechanical properties of the extracellular matrix influence fibronectin fibril assembly in vitro. Exp Cell Res (1995) 2.28
ERM proteins: from cellular architecture to cell signaling. Biol Cell (2000) 2.15
Modulation of contraction by gelation/solation in a reconstituted motile model. J Cell Biol (1991) 1.93
Factors influencing myofibroblast differentiation during wound healing and fibrosis. Cell Biol Int (1995) 1.86
Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med (1990) 1.83
The NH2-terminal peptide of alpha-smooth muscle actin inhibits force generation by the myofibroblast in vitro and in vivo. J Cell Biol (2002) 1.82
Heterogeneity of myofibroblast phenotypic features: an example of fibroblastic cell plasticity. Virchows Arch (1994) 1.79
Invited review: cross-bridge regulation by thin filament-associated proteins. J Appl Physiol (1985) (2001) 1.74
Effect of endothelin-1 on croton oil-induced granulation tissue in the rat. A pharmacologic and immunohistochemical study. Lab Invest (1992) 1.69
Direct targets of phosphoinositide 3-kinase products in membrane traffic and signal transduction. Trends Cell Biol (1998) 1.68
Prostacyclin derivatives prevent the fibrotic response to TGF-beta by inhibiting the Ras/MEK/ERK pathway. FASEB J (2002) 1.64
The role of integrin-linked kinase (ILK) in cancer progression. Cancer Metastasis Rev (2003) 1.59
Tension development during contractile stimulation of smooth muscle requires recruitment of paxillin and vinculin to the membrane. Am J Physiol Cell Physiol (2003) 1.56
Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem (2001) 1.52
Insights into the molecular mechanism of chronic fibrosis: the role of connective tissue growth factor in scleroderma. J Invest Dermatol (2004) 1.52
Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1. J Invest Dermatol (2001) 1.51
Differences in the regulation of fibroblast contraction of floating versus stressed collagen matrices. J Biol Chem (1999) 1.49
Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol (1997) 1.47
Cell locomotion forces versus cell contraction forces for collagen lattice contraction: an in vitro model of wound contraction. Tissue Cell (1990) 1.43
Dysregulation of transforming growth factor beta signaling in scleroderma: overexpression of endoglin in cutaneous scleroderma fibroblasts. Arthritis Rheum (2002) 1.40
Pathogenesis of scleroderma. Collagen. Rheum Dis Clin North Am (1996) 1.39
Molecular pharmacology of endothelin converting enzymes. Biochem Pharmacol (1996) 1.39
Quantitative analysis of collagen gel contractile forces generated by dermal fibroblasts and the relationship to cell morphology. J Cell Physiol (1996) 1.39
Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol (1995) 1.38
Endothelin antagonism in experimental hepatic fibrosis. Implications for endothelin in the pathogenesis of wound healing. J Clin Invest (1996) 1.38
Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. J Rheumatol (2000) 1.38
Smooth muscle differentiation in scleroderma fibroblastic cells. Am J Pathol (1990) 1.36
Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol (1992) 1.32
Endothelins. FASEB J (1991) 1.31
The endothelin system. A new target for therapeutic intervention. Circulation (1994) 1.30
Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis. Exp Cell Res (2000) 1.30
beta 1 integrin regulates fibroblast viability during collagen matrix contraction through a phosphatidylinositol 3-kinase/Akt/protein kinase B signaling pathway. J Biol Chem (2002) 1.29
A culture force monitor for measurement of contraction forces generated in human dermal fibroblast cultures: evidence for cell-matrix mechanical signalling. Biochim Biophys Acta (1994) 1.29
Epidermal growth factor induces acute matrix contraction and subsequent calpain-modulated relaxation. Wound Repair Regen (2002) 1.27
Functional cooperation between Smad proteins and activator protein-1 regulates transforming growth factor-beta-mediated induction of endothelin-1 expression. Circ Res (2003) 1.27
Akt signaling in skeletal muscle: regulation by exercise and passive stretch. Am J Physiol Endocrinol Metab (2003) 1.20
Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J Biol Chem (1995) 1.20
Purification and characterization of a phosphoramidon-sensitive endothelin-converting enzyme in porcine aortic endothelium. OFF. J Biol Chem (1993) 1.20
Transforming growth factor beta stimulates fibroblast-collagen matrix contraction by different mechanisms in mechanically loaded and unloaded matrices. Exp Cell Res (2002) 1.14
Mediation of transforming growth factor-beta(1)-stimulated matrix contraction by fibroblasts: a role for connective tissue growth factor in contractile scarring. Am J Pathol (2003) 1.11
Cell and molecular regulation of endothelin-1 production during hepatic wound healing. Mol Biol Cell (2003) 1.05
Smad3 mediates the TGF-beta-induced contraction of type I collagen gels by mouse embryo fibroblasts. Cell Motil Cytoskeleton (2003) 1.05
Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int J Immunopharmacol (1999) 1.05
On the mechanism of skin wound "contraction": a granulation tissue "knockout" with a normal phenotype. Proc Natl Acad Sci U S A (1995) 1.05
Endothelins produced by endothelial cells promote collagen gel contraction by fibroblasts. J Cell Biol (1991) 1.04
Contractile activity and smooth muscle alpha-actin organization in thrombin-induced human lung myofibroblasts. Am J Physiol Lung Cell Mol Physiol (2003) 1.03
A cytokine reborn? Endothelin-1 in pulmonary inflammation and fibrosis. Am J Respir Cell Mol Biol (2000) 1.03
Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis (1994) 1.03
Fibroblasts contracting collagen matrices form transient plasma membrane passages through which the cells take up fluorescein isothiocyanate-dextran and Ca2+. Mol Biol Cell (1997) 1.02
Role of connective tissue proteases in the pathogenesis of chronic inflammatory lung disease. Environ Health Perspect (1984) 1.02
Pulmonary fibrosis: cellular and molecular events. Pathol Int (2003) 0.96
Impaired regulation of collagen pro-alpha 1(I) mRNA and change in pattern of collagen-binding integrins on scleroderma fibroblasts. J Invest Dermatol (1993) 0.95
Scleroderma lung fibroblasts exhibit elevated and dysregulated type I collagen biosynthesis. Arthritis Rheum (1997) 0.92
PI3-kinase/Akt modulates vascular smooth muscle tone via cAMP signaling pathways. J Appl Physiol (1985) (2001) 0.88
Regulation of connective tissue synthesis in systemic sclerosis. Int Rev Immunol (1995) 0.87
Affinity and selectivity of PD156707, a novel nonpeptide endothelin antagonist, for human ET(A) and ET(B) receptors. J Pharmacol Exp Ther (1997) 0.86
Endothelins. Blood Vessels (1990) 0.85
Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol (1998) 0.84
Expression of endothelin and ETB receptors in the megakaryoblastic MEG-01 cell line. J Cardiovasc Pharmacol (1995) 0.83
Mitogenic activity of endothelin on human cultured prostatic smooth muscle cells. Eur J Pharmacol (1998) 0.83
Collagen synthesis and degradation by systemic sclerosis lung fibroblasts. Responses to transforming growth factor-beta. Chest (1991) 0.82
Endothelin plays a role in the maintenance of blood pressure in normotensive guinea pigs. Life Sci (1994) 0.77
Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2009) 12.05
Bosentan therapy for pulmonary arterial hypertension. N Engl J Med (2002) 11.18
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62
TGF-beta signaling and the fibrotic response. FASEB J (2004) 9.81
A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med (2011) 6.40
A myocardial lineage derives from Tbx18 epicardial cells. Nature (2008) 6.15
2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum (2013) 5.99
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet (2011) 5.94
Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol (2005) 5.88
An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med (2012) 5.37
All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci (2006) 5.18
Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med (2003) 4.03
Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am J Respir Crit Care Med (2008) 3.97
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med (2011) 3.85
Sarcoidosis. Lancet (2003) 3.60
BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 3.49
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum (2006) 3.45
Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A (2004) 3.34
BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 3.23
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet (2009) 3.21
Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med (2008) 3.19
Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat Genet (2013) 3.17
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis (2013) 3.11
Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med (2003) 3.07
Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med (2002) 3.06
A polymorphism in the CTGF promoter region associated with systemic sclerosis. N Engl J Med (2007) 2.95
Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum (2007) 2.80
Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med (2003) 2.78
Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med (2008) 2.65
Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem (2003) 2.63
The bone marrow functionally contributes to liver fibrosis. Gastroenterology (2006) 2.52
Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest (2010) 2.51
Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy? Matrix Biol (2002) 2.45
Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. J ECT (2012) 2.43
Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine Growth Factor Rev (2008) 2.40
Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-beta 2 in fibroblasts. J Biol Chem (2003) 2.35
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis (2010) 2.30
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18
Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax (2013) 2.17
Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension. Eur Heart J (2006) 2.16
Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease. Thorax (2006) 2.10
Negligible contribution of bone marrow-derived cells to collagen production during hepatic fibrogenesis in mice. Gastroenterology (2009) 2.06
Efficacy of the specific endothelin a receptor antagonist zibotentan (ZD4054) in colorectal cancer: a preclinical study. Mol Cancer Ther (2013) 2.05
CCN2 is necessary for adhesive responses to transforming growth factor-beta1 in embryonic fibroblasts. J Biol Chem (2006) 1.96
Prognostic implications of histologic patterns in multiple surgical lung biopsies from patients with idiopathic interstitial pneumonias. Chest (2004) 1.95
Inducible lineage-specific deletion of TbetaRII in fibroblasts defines a pivotal regulatory role during adult skin wound healing. J Invest Dermatol (2008) 1.92
All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med (2014) 1.89
Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol (2006) 1.87
CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol Biol Cell (2004) 1.83
Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res Ther (2005) 1.81
Identification of novel genetic markers associated with clinical phenotypes of systemic sclerosis through a genome-wide association strategy. PLoS Genet (2011) 1.80
The role of connective tissue growth factor, a multifunctional matricellular protein, in fibroblast biology. Biochem Cell Biol (2003) 1.80
The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2002) 1.80
CTGF expression in mesangial cells: involvement of SMADs, MAP kinase, and PKC. Kidney Int (2002) 1.77
An essential role for resident fibroblasts in experimental lung fibrosis is defined by lineage-specific deletion of high-affinity type II transforming growth factor β receptor. Am J Respir Crit Care Med (2010) 1.76
Mechanisms and consequences of fibrosis in systemic sclerosis. Nat Clin Pract Rheumatol (2006) 1.73
Flexibility and diversity in consultant careers. Clin Med (2002) 1.71
Platelet-derived growth factor-beta receptor activation is essential for fibroblast and pericyte recruitment during cutaneous wound healing. Am J Pathol (2006) 1.70